Paul E. McKeever M.D., Ph.D.
Associate Professor
Campus Address: 
M4207 MSI
1301 Catherine Road
Ann Arbor, Michigan 48109-0602
Phone: 734/936-1889
FAX: 734/763-6476
paulmcke@umich.edu

Annual Report | Biography | Clinical Interests | Research Interests | Selected Publications

Departmental Annual Reports

2000-2001 | 1999-2000

Brief Biography

Dr. McKeever received his undergraduate degree from Brown University, Providence, Rhode Island, his M.D. from the University of California, Davis in 1972, and his Ph.D. in Experimental Pathology from the University of South Carolina in 1976. After working at the National Institute of Health and a faculty appointment in the Department of Pathology, Uniformed Services, University Health Sciences, he came to the University of Michigan in 1983. He has served as the Chief of the Section of Neuropathology since 1983 and is the Director of the Neuropathology Residency.

Dr. McKeever' s main clinical and research interests involve brain and pituitary tumors. Since 1995 and 1997, he has served on the Editorial Boards of the Journal of Neuro-Oncology and the Journal of Histochemistry and Cytochemistry, respectively. Since 1997, he has been editor of the Histochemical Society Newsletter.

Dr. McKeever applies molecular markers to clinical and diagnostic problems in neuro-oncology and neuro pathology. For example, tumor progression in human gliomas is under study. At present it is not possible to determine which astrocytomas will rapidly progress to more malignant astrocytic gliomas and which will remain stable for years. Markers of cellular proliferation like MIB-1 nuclear antigen are being used on these gliomas to determine which markers will identify subsets of tumors of prognostic importance. Possible oncogenetic mechanisms of "hot spots" of cellular proliferation can be probe by in situ hybridization for chromosomal markers to determine whether cytogenetic abnormalities underly these proliferations.

Tumor regression is associated with antigenic instability in gliomas, either as a result of growth of different cell populations, or of modulation of expression of the genome. Research activities have been directed towards understanding the basic biologic mechanisms of its antigenic instability.

Clinical Interests

Pathology,brain tumors, pituitary tumors, neurotoxicity and neuropathology.

Research Interests

Brain tumors, pituitary tumors, neurotoxicity, and neuropathology.

Molecular markers are applied to clinical and diagnostic problems in neuro-oncology and neuropathology. For example, tumor progression in human gliomas is under study. At present it is not possible to determine which astrocytomas will rapidly progress to more malignant astrocytic gliomas and which will remain stable for years. Markers of cellular proliferation like MIB-1 nuclear antigen are being used on these gliomas to determine which makers will identify subsets of tumors of prognostic importance. Possible oncogenetic mechanisms of "hot spots" of cellular proliferation can be probed by in situ hybridization for chromosomal markers to determine whether cytogenetic abnormalities underly these proliferations.

Tumor progression is associated with antigenic instability in gliomas, either as a result of growth of different cell populations, or of modulation of expression of the genome. Research activities have been directed towards understanding the basic biologic mechanisms of this antigenic instability.

Selected Publications

Kamchonwongpaisan S, McKeever PE, Hossler P, Ziffer H, Meshnick SR. Artemisinin neurotoxicity: Neuropathology in rats and mechanistic studies in vitro. Am. J. Trop. Med. Hyg. 56: 7-12, 1997.